David Adair MD

Dave has worked with the partners of Solas BioVentures Fund since 2004 and was a founding member of the fund in 2014. Dave is a long-time physician, educator, administrator, innovator, and biotech/med-tech investor with nearly 20 years of experience in angel and venture investing. Dave recently retired as Professor and Vice Chairman of the Department of Obstetrics and Gynecology at the University of Tennessee College of Medicine. Dave is Board certified in Maternal-Fetal Medicine, Obstetrics and Gynecology, and Hypertension, with special expertise in Critical Care. Dave received a BS in Biology from Morehead State University, where he is Hall of Fame member, and is a graduate from The University Tennessee Chattanooga with a Master of Business Administration with a concentration in Healthcare. Dave earned his medical degree from the Joan C. Edwards College of Medicine at Marshall University and completed residency at the University of Florida Health Science Center and Fellowship training at Wake Forest University.

Besides serving as the Chairman of the board at Aegea Medical, Dave serves as a director Biostable SE, Arrivo Bio Ventures, Advanced Catheter Therapies, PreTel Health, Velo Bio, and Anogen Life Sciences. Dave and his colleagues have invested in many cutting edge and disruptive medical device and biotech companies, including Veran Medical Technologies (where he served previously as a board director), Addrenex, acquired by Sciele/Shionogi (OTCMKTS:SGIOY); Neuronex, acquired by Acorda (NASDAQ:ACOR); Velo Bio, acquired by AMAG Pharmaceuticals (NASDAQ:AMAG); Aerial Bio, acquired by Jazz Pharmaceuticals (NASDAQ:JAZZ); and NxThera, acquired by Boston Scientific (NYSE:BSX). Dave also founded Glenveigh Medical, which had a therapeutic out-licensed to Protherics (FTSE:PTIL) and medical devices acquired by Clinical Innovations.

Important Safety Information:

The Mara Water Vapor Ablation System is indicated to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia due to benign causes for whom childbearing is complete. Pregnancy following the Mara procedure can be dangerous. The Mara procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. As with all surgical procedures, there are risks and considerations associated with the use of the Mara Water Vapor Ablation System. Please refer to the device labeling for a detailed discussion of the device’s intended use, relevant warnings, precautions, side effects, and contraindications.